Protective effect of melatonin versus montelukast in cisplatin-induced seminiferous tubule damage in rats
| Autor: | Noha Zahran, Rana Elabd, Adel El-shafaei, Amany K. Elshorbagy, Rania Abdelmaksoud |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cyclopropanes Male endocrine system medicine.medical_specialty Urology medicine.medical_treatment Intraperitoneal injection Drug Evaluation Preclinical Antineoplastic Agents Acetates Sulfides medicine.disease_cause Testicular Diseases Antioxidants Melatonin 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine medicine Animals Rats Wistar Montelukast Cisplatin 030219 obstetrics & reproductive medicine business.industry Body Weight General Medicine Organ Size Seminiferous Tubules Sperm Semen Analysis Oxidative Stress 030104 developmental biology Seminiferous tubule medicine.anatomical_structure Toxicity Quinolines Leukotriene Antagonists business hormones hormone substitutes and hormone antagonists Oxidative stress medicine.drug |
| Zdroj: | Andrologia. 50(9) |
| ISSN: | 1439-0272 |
| Popis: | We compared the protective effects of melatonin and montelukast against cisplatin-induced testicular damage. Adult male rats were assigned to one of four groups: a control group, a cisplatin (Cis) group treated with a single intraperitoneal injection of 7 mg/kg cisplatin, a cisplatin + melatonin group (Cis-Mel) and a cisplatin + montelukast group (Cis-Mon) each treated with the same dose of cisplatin together with either oral melatonin (20 mg/kg) or oral montelukast (10 mg/kg) in 2 ml water from day 1 to day 10 starting on the day of the cisplatin injection. Cisplatin-induced oxidative stress, with a significant increase in testicular malonedialdehyde (MDA), decreased testicular glutathione (GSH), histological testicular damage and body weight loss. Additionally, increased abnormal sperm forms and decreased count and motility were noted. Melatonin and montelukast both rescued GSH concentrations, increased sperm count and motility and decreased abnormal forms. Montelukast resulted in better rescue of weight loss, while greater improvement in sperm count and testicular pathology, and a trend for decreased MDA were noted with melatonin. These findings suggest that melatonin and montelukast protect against different aspects of cisplatin-induced toxicity. Future studies should assess whether both drugs may have additive benefit when used in combination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|